PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Vogel, G.F.* ; Mozer-Glassberg, Y.* ; Landau, Y.E.* ; Schlieben, L.D. ; Prokisch, H. ; Feichtinger, R.G.* ; Mayr, J.A.* ; Brennenstuhl, H.* ; Schröter, J.* ; Pechlaner, A.* ; Alkuraya, F.S.* ; Baker, J.J.* ; Barcia, G.* ; Baric, I.* ; Braverman, N.* ; Burnyte, B.* ; Christodoulou, J.* ; Ciara, E.* ; Coman, D.* ; Das, A.M.* ; Darin, N.* ; Della Marina, A.* ; Distelmaier, F.* ; Eklund, E.A.* ; Ersoy, M.* ; Fang, W.* ; Gaignard, P.* ; Ganetzky, R.D.* ; Gonzales, E.* ; Howard, C.R.* ; Hughes, J.* ; Konstantopoulou, V.* ; Kose, M.* ; Kerr, M.* ; Khan, A.* ; Lenz, D.* ; McFarland, R.* ; Margolis, M.G.* ; Morrison, K.* ; Müller, T.* ; Murayama, K.* ; Nicastro, E.* ; Pennisi, A.* ; Peters, H.* ; Piekutowska-Abramczuk, D.* ; Rötig, A.* ; Santer, R.* ; Scaglia, F.* ; Schiff, M.* ; Shagrani, M.* ; Sharrard, M.* ; Soler-Alfonso, C.* ; Staufner, C.* ; Storey, I.* ; Stormon, M.* ; Taylor, R.W.* ; Thorburn, D.R.* ; Teles, E.L.* ; Wang, J.S.* ; Weghuber, D.* ; Wortmann, S.*

Genotypic and phenotypic spectrum of infantile liver failure due to pathogenic TRMU variants.

Genet. Med. 25:100314 (2022)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Purpose: The study aimed to define the genotypic and phenotypic spectrum of reversible acute liver failure (ALF) of infancy resulting from biallelic pathogenic TRMU variants and to determine the role of cysteine supplementation in its treatment. Methods: Individuals with biallelic (likely) pathogenic variants in TRMU were studied through an international retrospective collection of de-identified patient data. Results: In 62 individuals, including 30 previously unreported cases, we described 48 (likely) pathogenic TRMU variants, of which, 18 were novel. Of these 62 individuals, 42 were alive at a median age of 6.8 (0.6-22) years after a median follow up of 3.6 (0.1-22) years. The most frequent finding, occurring in all but 2 individuals, was liver involvement. ALF occurred only in the first year of life and was reported in 43 of 62 individuals, 11 of whom received liver transplantation. Loss-of-function TRMU variants were associated with poor survival. Supplementation with at least 1 cysteine source, typically N-acetylcysteine, improved survival significantly. Neurodevelopmental delay was observed in 11 individuals and persisted in 4 of the survivors, but we were unable to determine whether this was a primary or a secondary consequence of TRMU deficiency. Conclusion: In most patients, TRMU-associated ALF is a transient, reversible disease and cysteine supplementation improved survival.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
8.864
2.825
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Acute Liver Failure ; Cysteine ; Liver Transplantation ; Mitochondrial Disease ; Treatment; Mitochondrial; Deficiency; Diagnosis; Disease
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1530-0366
e-ISSN 1098-3600
Zeitschrift Genetics in Medicine
Quellenangaben Band: 25, Heft: 6, Seiten: , Artikelnummer: 100314 Supplement: ,
Verlag Lippincott Williams & Wilkins
Verlagsort Baltimore, Md.
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Neurogenomics (ING)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-503292-001
Förderungen UK NIHR Biomedical Research Centre for Ageing and Age-related Disease award
Lily Foundation
Medical Research Council
Medical Research Council International Centre for Genomic Medicine in Neuromuscular Disease
Mitochondrial Disease Patient Cohort (United Kingdom)
Wellcome Trust Centre for Mitochondrial Research
Saol Therapeutics
Optimizing diagnostics and treatment for patients with mitochondrial diseases FWF
PTC Therapeutics
Courage for a Cure Foundation
Mervar Foundation
Frontiers of Congenital Disorders of Glycosylation Consortia (FCDGC)
North American Mitochondrial Disease Consortia
National Institutes of Health
European Reference Network for Hereditary Metabolic Disorders (MetabERN)
MitoCanada
Astellas Pharma Inc.
UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children
King Salman Center for Disability Research
Bavarian State Ministry of Health and Care
BMBF (German Federal Ministry of Education and Research)
Victorian Government's Operational Infrastructure Support program
National Health and Medical Research Council (NHMRC)
New South Wales Office of Health and Medical Research Council Sydney Genomics Collaborative grant
Pathological Society
DOI 10.1016/j.gim.2022.09.015
WOS ID 001017980000001
Scopus ID 85140967450
PubMed ID 36305855
Erfassungsdatum 2022-12-03
[➜Korrektur melden]